UK consumer goods giant Reckitt Benckiser LLC created its K-Y-branded premature ejaculation spray without stealing trade secrets from a small pharmaceutical company, according to a jury in a New Jersey federal court.
Absorption Pharmaceuticals LLC failed to show that the information at issue was protected as a trade secret or that Reckitt acted dishonestly during the company's acquisition negotiations, according to the jury.
Las Vegas-based Absorption had sought more than $450 million in damages. Reckitt had no
In a 2017 lawsuit, Absorption claimed that its Promescent lidocaine spray could treat premature ejaculation in the same way that Viagra treated erectile dysfunction. Absorption claimed it shared secrets with Reckitt during discussions about a possible acquisition.
Senior Reckitt workers tried samples of Promescent and indicated it actually works, according to the lawsuit. Absorption allegedly supplied thousands of bottles of Promescent to Reckitt for testing, according to the lawsuit.
Reckitt and Absorption finished their negotiations in 2015, and K-Y Duration commenced production in 2016. Reckitt also allegedly coerced Amazon and Target to lower Promescent's visibility in an attempt to drive the company out of business.
Reckitt also committed fraud, according to the lawsuit, by making misleading assertions about its intentions to buy Absorption, which persuaded it to reveal its secrets and turn down an offer to be acquired by another business.
In a court filing this month, Reckitt contended that it had not misled Absorption and that it had failed to discover any stolen trade secrets.


Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war?
xAI Faces Lawsuit Over Grok AI-Generated Sexual Content Involving Minors
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Federal Judge Blocks Pentagon's Restrictive Press Access Policy
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
ICE Arrests Colombian Journalist in Tennessee, Trump Administration Says She Will Receive Due Process
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations
9 Tips for Avoiding Tax Season Cyber Scams 



